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background: Patients with peripheral pulmonary stenosis (PPS) are at risk of right ventricular (RV) failure, arrhythmias, and sudden death as 
a result of extreme pressure load imposed by diffuse anatomic obstruction of the pulmonary vasculature. PPS can be managed surgically and by 
transcatheter angioplasty and stent placement which acutely can relieve obstructions, but they often recur. Approximately 1/3 of PPS patients with 
arteriopathies and/or Tetralogy of Fallot (TOF) develop in-stent stenosis (ISS) with subsequent stent obstruction. Supported by literature showing 
that local or systemic rapamycin reduces ISS in adult coronary arteries and a dosing and safety profile established in the pediatric transplant 
population, we have used oral rapamycin to reduce recurrence of pulmonary artery (PA) obstructions due to ISS.
methods: We have treated 8 patients (1.5-16 years) with severe PPS due to Williams or Alagille syndrome and/or TOF. All patients had ISS and 
either RV hypertension, pulmonary blood flow maldistribution, and/or segmental pulmonary hypertension. Monthly labs were monitored and follow-
up catheterization was performed when clinically indicated, typically within 6 months.
results: All 8 treated patients achieved targeted systemic levels of rapamycin (6-10 ng/mL). Two patients experienced possibly drug-related 
adverse events (diarrhea and a gastrointestinal bleed related to an indwelling feeding tube). Five patients treated with short-term (1-3 mo) 
rapamycin have shown at least mild angiographic ISS improvement. The child with the longest (27 mo) follow-up has severe Williams arteriopathy. 
She has experienced marked reduction in ISS which correlated temporally with initiation of rapamycin, her baseline RV pressure has decreased 
from 150% to 60 % of systemic, and her RV function has normalized. Prior to rapamycin therapy she developed recurrent fatigue and tachypnea and 
required catheterizations every 3-4 mo due to ISS, while she is now asymptomatic at 1 year after catheterization.
conclusions: This initial clinical experience suggests that systemic rapamycin may provide a novel and safe medical approach to reduce ISS 
following PA stent placement.
